Page 1

Frontier Pharma: Psoriasis - Identifying And Commercializing First-In-Class Innovation Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly impairs the patient’s physical and mental wellbeing. The primary cause of


psoriasis is unknown, as are the mechanisms that lead to immune cells directing inflammatory responses towards the skin. Within the lucrative autoimmune market, the psoriasis market has grown considerably due to the repositioning of all three marketed Tumor Necrosis Factor (TNF) inhibitors: Humira (adalimumab) and Enbrel (etanercept) which were originally approved for rheumatoid arthritis, and also Remicade (infliximab), the first biologic to be approved for Crohn’s disease, an autoimmune disease which largely affects the gastrointestinal system. Browse Full Report With Toc: http://www.marketresearchreports.biz/analysisdetails/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-classinnovation

Table of Contents


1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 The Case for Innovation 2.1 Growing Opportunities for Biologic Products 2.2 Diversification of Molecular Targets 2.3 Innovative First-in-Class Product Developments Remain Attractive 2.4 Changes in the Clinical and Commercial Environment Will be More Favorable to Products That Target Niche Indications and Patient Populations 2.5 Innovation in Psoriasis 3 Clinical and Commercial Landscape 3.1 Disease Introduction


3.2 Epidemiology 3.3 Etiology 3.3.1 Genetic Predisposition 3.3.2 Environmental Factors 3.4 Pathophysiology 3.4.1 Keratinocytes 3.4.2 Dendritic Cells 3.4.3 T-Cells 3.4.4 Angiogenesis 3.4.5 Growth Factors 3.5 Symptoms and Co-morbidities 3.5.1 Skin Manifestations 3.5.2 Psoriatic Arthritis 3.5.3 Uveitis


3.5.4 Cardiovascular Disease 3.5.5 Psychological Impact 3.6 Diagnosis of Psoriasis 3.6.1 Diagnosis of Psoriatic Arthritis 3.7 Treatment 3.7.1 Pharmacological Therapies 3.7.2 Topical Medications 3.7.3 Systemic Medications 3.7.4 Non-Pharmacological Therapies 3.7.5 Combination and Rotational Therapies 3.8 Overview of Marketed Products for Psoriasis 3.8.1 Oral Non-Biologic DMARDs 3.8.2 Off-Label Non-Biologic DMARDs 3.8.3 Biologics


3.8.4 Comparative Efficacy and Safety of Marketed Products 3.8.5 Unmet Need To Get Download Full Report with Toc: http://www.marketresearchreports.biz/sample/sample/206412

4 Assessment of Psoriasis Pipeline and Innovation 4.1 Overview 4.2 Comparative Efficacy and Safety of Pipeline Programs 4.3 Comparative Distribution of Programs in the Psoriasis Market and Pipeline by Therapeutic Target Family 4.4 Comparative Distribution of Programs with First-in-Class and Established Molecular Targets 4.5 Pipeline Programs Targeting Established Molecular Targets


4.6 First-in-Class Pipeline Programs with Novel Molecular Targets 5 First-in-Class Target and Pipeline Program Evaluation 5.1 Cytokines and Receptors 5.1.1 Pipeline Programs Targeting Tumor Necrosis Factor Receptors 5.1.2 Pipeline Programs Targeting Interleukin-6 5.1.3 Pipeline Programs Targeting Interleukin-8 5.1.4 Pipeline Programs Targeting Interleukin-17 5.1.5 Pipeline Programs Targeting Interferon-? 5.2 B and T Cell Antigens 5.2.1 Pipeline Programs Targeting Cluster of Differentiation 4 5.2.2 Pipeline Programs Targeting Cluster of Differentiation 28 5.3 Intracellular Kinases 5.3.1 Pipeline Programs Targeting Interleukin-1 Receptor-Associated Kinase-4


5.4 Nuclear Receptors 5.4.1 Pipeline Programs Targeting Retinoic Acid Receptor-Related Orphan Receptor 5.5 Growth Factors 5.5.1 Pipeline Programs Targeting Transforming Growth Factor-Ă&#x; Receptor 5.5.2 Pipeline Programs Targeting Insulin Receptor Substrate 5.6 Ion Channels 5.6.1 Pipeline Programs Targeting Calcium Release-Activated Calcium Channel 5.7 Integrins 5.7.1 Pipeline Programs Targeting Vascular Adhesion Protein-1 5.8 Other 5.8.1 Pipeline Programs Targeting F1F0-Adenosine Triphosphate Synthase 5.8.2 Pipeline Programs Targeting Cathepsin S


5.9 Conclusion 6 Deals and Strategic Consolidations 6.1 Licensing Agreements 6.2 Major Co-development Deals 6.3 First-in-Class Developmental Programs Not Involved in Co-Development or Licensing Deals To Read Complete Report with Toc: http://www.marketresearchreports.biz/analysis/206412

7 Appendix 7.1 Abbreviations 7.2 References


7.3 Methodology 7.4 Contact Us 7.5 Disclaimer Table 1: Psoriasis Market, Global, First-in-Class Interferon-? Inhibitors, Pipeline Development Table 2: Psoriasis Market, Global, First-in-Class F1F0-Adenosine Triphosphate Synthase Modulators, Pipeline Development Table 3: Abbreviations Figure 1: Psoriasis, Global, Treatment Algorithm Figure 2: Psoriasis Market, Global, Comparative Safety and Efficacy, 2013 - 1 Figure 3: Psoriasis Market, Global, Comparative Safety and Efficacy, 2013 - 2 Figure 4: Psoriasis Market, Global, Pipeline Overview, 2013 Figure 5: Psoriasis Market, Global, Comparative Safety and Efficacy of Pipeline Products, 2013


Figure 6: Psoriasis, Global, Comparative Distribution of Marketed and pipeline Products by Target Family Figure 7: Psoriasis Market, Global, Pipeline, Comparative Distribution of Programs by Established and First-in-Class Targets, 2013 Figure 8: soriasis Market, Global, Pipeline Products with Established Targets, 2013 Figure 9: Psoriasis Market, Global, Pipeline Products with First-in-Class Targets, 2013 Figure 10: Psoriasis Market, Global, First-in-Class Tumor Necrosis Factor-a Receptor Modulators, Pipeline Development Figure 11: Psoriasis Market, Global, First-in-Class Interleukin-6 Inhibitors, Pipeline Development Figure 12: Psoriasis Market, Global, First-in-Class Interleukin-8 Inhibitors, Pipeline Development


Figure 13: Psoriasis Market, Global, First-in-Class Interleukin-17 Inhibitors, Pipeline Development Figure 14: Psoriasis Market, Global, First-in-Class Cluster of Differentiation 4 Modulators, Pipeline Development Figure 15: Psoriasis Market, Global, First-in-Class Cluster of Differentiation 28 Modulators, Pipeline Development Figure 16: Psoriasis Market, Global, First-in-Class Interleukin-1 Receptor Associated Kinase-4 Inhibitors, Pipeline Development Figure 17: Psoriasis Market, Global, First-in-Class Retinoic Acid ReceptorRelated Orphan Receptor Inhibitors, Pipeline Development Figure 18: Psoriasis Market, Global, First-in-Class Transforming Growth Factor-Ă&#x; Receptor Modulators, Pipeline Development Figure 19: Psoriasis Market, Global, First-in-Class Insulin Receptor Substrate Modulators, Pipeline Development


Figure 20: Psoriasis Market, Global, First-in-Class Calcium Release-Activated Calcium Channel, Pipeline Development Figure 21: Psoriasis Market, Global, First-in-Class Vascular Adhesion Protein-1 Inhibitors, Pipeline Development Figure 22: Psoriasis Market, Global, First-in-Class Cathepsin S Inhibitors, Pipeline Development Figure 23: Psoriasis Market, Global, Licensing Agreement Analysis 1, 2006– 2014 Figure 24: Psoriasis Market, Global, Licensing Agreement Analysis 2, 2006– 2014 Figure 25: Psoriasis Market, Global, Licensing Agreement Deal Analysis, 2006–2014 Figure 26: Psoriasis Market, Global, Co-Development Deal Analysis, 2006– 2014 - 1


Figure 27: Psoriasis Market, Global, Co-Development Deal Analysis, 2006– 2014 - 2 Figure 28: Psoriasis Market, Global, First-in-Class Programs with no Recorded Prior Deal Involvement, 2006–2014

Contact US: Office: United States State Tower 90 State Street, Suite 700 Albany, NY 12207 United States


Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

New Research-Frontier Pharma: Psoriasis - Identifying And Commercializing First-In-Class Innovation  

MarketResearchReports.Biz presents this most up-to-date research on "Research Report On Frontier Pharma: Psoriasis - Identifying And Commerc...

Read more
Read more
Similar to
Popular now
Just for you